Dr. Bansal joined the faculty at Mount Sinai in 2001 after completing Gastroenterology Fellowship at the University of Pennsylvania. In 2002 she became the Transplant Hepatology Fellowship Director, leading one of the largest transplant hepatology fellowships in the United States. While remaining clinically active, she has also developed an NIH-funded basic research program focusing on understanding underlying molecular mechanisms of liver fibrosis/cirrhosis in an effort to develop novel anti-fibrotic therapies. Her current research interests focus on how HIV may promote hepatic inflammation and fibrosis as well as novel treatments for Non-Alcoholic Steatohepatitis (NASH). She became the Director of Translational Research in the Division of Liver Diseases in 2013 and is the principal investigator in a number of clinical trials for the treatment of Hepatitis C and NASH. Since 2015 she has also served as the Chief Medical Officer of Mount Sinai Care LLC and Deputy Chief Medical Officer for Mount Sinai Health Partners, the population health platform the entire Mount Sinai Health System. In this latter role, Dr. Bansal has the opportunity to translate findings from research/clinical trials to address population health needs in an ever-changing healthcare landscape.
AIDS/HIV, Cell Biology, Chemokines, Fibrosis, Hepatitis C Virus, Knockout Mice, Molecular Biology, Regeneration, Transcription Factors, Transcriptional Activation and Repression, Viruses and Virology
Biophysics and Systems Pharmacology [BSP], Cancer Biology [CAB]
AB, Harvard University
MD, Cornell University Medical College
MD, New York Presbyterian - Weill Cornell Medical Center
, The New York Hospital-Cornell Medical Center
Residency, Internal Medicine
New York Presbyterian - Weill Cornell Medical Center
Hospital of the University of Penn.
Dr. Harold and Golden Lamport Research Award
Regal Awards: Research Excellence in GI and Liver
Komarov Competition-Basic Science. Philadelphia, Pennsylvania
Awarded to GI fellow performing most outstanding basic research in all Philadelphia programs
David E. Rogers Memorial Prize
The New York Hospital-Cornell University Medical College
Awarded for most outstanding research during residency training
C. Richard Bowman Memorial Award
The New York Hospital-Cornell University Medical College
Miles and Shirley Fiterman Basic Research Award
American Gastroenterological Association
Specific Clinical/Research Interests: Role of chemokine receptors, CXCR4 and CCR5, on stellate cell biology and fibrogenesis; molecular regulation of hepatic fibrosis and regeneration
Current Students: Yedidya Saiman
Postdoctoral Fellows: Ana Tuyama; Ritu Agarwal
Research Personnel: Feng Hong
Summary of Research Studies:
Brief Biosketch and Research Interests Dr. Bansal joined the faculty at Mount Sinai in 2001 after completing Gastroenterology Fellowship at the University of Pennsylvania. In 2002 she became the Hepatology Fellowship Director, leading one of the largest hepatology fellowships in the United States. While remaining clinically active, she has also developed an NIH-funded basic research program focusing on understanding underlying molecular mechanisms of liver fibrosis/cirrhosis in an effort to develop novel anti-fibrotic therapies. Her research interests focus on the role of Matrix Metalloproteinase-2 in liver fibrosis and regeneration and Role of the chemokine receptors, CXCR4 and CCR5, on stellate cell biology and fibrogenesis. The latter has great implications in understanding mechanism of HCV- and HIV/HCV-induced liver disease.
A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection who Have Not Received an NS5A Inhibitor
The purpose of this study is to determine the efficacy, safety, and tolerability of sofosbuvir (SOF)/velpatasvir (VEL)/GS-9857 in comparison with SOF/VEL in subjects infected with HCV. Information about any side effects that may occur will also be collected. Subjects with HCV ...
A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic Genotype 3 HCV Infection and Cirrhosis
The purpose of this study is to determine the efficacy, safety, and tolerability of SOF/VEL/GS-9857 in comparison to SOF/VEL in patients infected with HCV. Information about any side effects that may occur will also be collected. This is a randomized, open-label study. Su...
Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis (CENTAUR)
The purpose of this study is to look at how well the study drug CVC (Cenicriviroc) works for the treatment of NASH with liver fibrosis and also how safe and effective the study drug is when compared to a placebo. A placebo looks like a drug but does not contain the study drug’s a...
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled,Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis
The purpose of this study is to look at how well the study drug OCA (Obeticholic Acid) works for the treatment of NASH with liver fibrosis and also how safe and effective the study drug is when compared to a placebo. A placebo looks like a drug but does not contain the stud...
Bansal MB, Friedman SL. Reversal of Hepatic Fibrosis-Fact or Fantasy?. Hepatology 2006; 43: S82-88.
Kodali R, Hajjou M, Berman AB, Schecter AD, Zhang S, Pan JJ, Bansal MB. Chemokines Induce Matrix Metalloproteinase-2 Through Activation of Epidermal Growth Factor Receptor in Arterial Smooth Muscle Cells. Cardiovascular Research 2006; 69: 706-715.
Bansal MB, Kovalovich K, Li W, Gupta R, Taub RA, Alvarez CE, Safadi R, Radbill B, Friedman SL, Agarwarl A. Interleukin-6 Protects Hepatocytes from CCl4- Mediated Necrosis and Apoptosis in Mice by Reducing MMP-2 Expression. Journal of Hepatology 2005; 42: 548-556.
Safadi R, Ohta M, Alvarez CE, Friedman SL, Bansal MB, Mehal WZ, Fiel MI. Immune Stimulation of Hepatic Fibrogenesis by CD8 Lymphocytes and its Attenuation by Transgenic Interleukin 10 from Hepatocytes. Gastroenterology 2004; 127: 870-882.
Friedman SL, Bansal MB. The enlarging role of matrix metalloproteinases in liver injury - beyond scar degradation. J Hepatol 2002 Aug; 37(2): 293-294.
Friedman SL, Bansal MB, editors. Fibrogenesis. San Diego, Elsevier,Academic Press; pp34-38.
Hong F MD, Tuyama A, Agarwal R, Gupta R, Cheng X, Garg A, Inoue YM, Fiel M MD, Schwartz M MD, Schwartzkopf M, Schecter AD, Bansal MB MD. Hepatic Stellate Cells Express Functional CXCR4: Role in Stromal Cell Derived Facter -1a medicated Stellate Cell Activation. Hepatology 2009; 49: 2005-2067.
Tuyama AC, Hong F MD, Saiman Y, Wang C MD, Mosoian A, Chen P, Chen BK, Klotman M MD, Bansal MB MD. HIV-1 Infects Human Hepatic Stellate Cells and Promotes Collagen I and MCP-1 Expression: Implications for hepatic fibrosis in HIV/HCV co infection. Hepatology 2010; 52: 612-621.
Radbill B MD, Gupta R, Ramirez MM, DiFeo A, Martignetti J, Alvarez C MD, Friedman SL MD, Narla G MD, Vrabie R, Saiman Y, Bowles R, MB Bansal. Loss of Matrix Metalloproteinase-2 Amplifies Murine Toxin INduced Liver Fibrosis by Upregulating Collagen I Expression. Digestive Diseases and Sciences 2011; 56: 406-416.
Bansal MB MD, Friedman SL MD. Hepatic Fibrogenesis. In: Sherlock's Diseases of the Liver and Biliary System. pp94-101.
Bansal MB MD, Blackard J. Effect of HIV on Liver Cell Populations. In: HIV and Liver Diseases. Springer;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Bansal did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.